| abstract |
The target is to provide PDE IV inhibitors whichnhave a highly potent anti-asthmatic and/or COPD-prophylactic/therapeuticnprofile with unexpectedlynexcellent safety. A compound of the formula (1):n nwherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl,nwhich may be unsubstituted or optionally substituted withnone or more members selected from the group consisting ofnhydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy,nlower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl,ncarboxy-lower alkylene, lower alkoxycarbonyl-lowernalkylene, lower alkylsulfonyl, lower alkylsulfonylamino,nand ureido; R 1 is a group selected from the groupnconsisting of hydrogen, hydroxyl, halogen, cyano, nitro,nlower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R 2 nis hydrogen or lower alkyl; and m is an integer of 1 to 3;nor a pharmaceutically acceptable salt thereof, possessesnhighly excellent PDE IV-specific inhibitory actions and isnuseful as an anti-asthmatic drug and/or a prophylactic/therapeuticndrug for COPD with high safety. |